{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:36:59Z","timestamp":1792010219273,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lpm.2017.01.016","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T09:32:34Z","timestamp":1488274354000},"page":"e41-e51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"P2","title":["The challenge of the new tuberculosis drugs"],"prefix":"10.1016","volume":"46","author":[{"given":"Simon","family":"Tiberi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruaridh","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Caminero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Abdo","family":"Arbex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2017.01.016_bib0005","series-title":"Global tuberculosis report 2016","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.lpm.2017.01.016_bib0010","unstructured":"World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015 http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB134\/B134_12-en.pdf?ua=1 [accessed on October 2nd, 2016]."},{"key":"10.1016\/j.lpm.2017.01.016_bib0015","series-title":"WHO treatment guidelines for drug-resistant tuberculosis. 2016\u00a0update. WHO\/HTM\/TB 2016. 04","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.lpm.2017.01.016_bib0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-76-3-112-6-397","article-title":"USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results","volume":"112","author":"Combs","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14787210.2017.1247692","article-title":"Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers","volume":"15","author":"Alffenaar","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.lpm.2017.01.016_bib0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0040","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/cid\/ciu619","article-title":"Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis","volume":"59","author":"Bastos","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0045","series-title":"Treatment of tuberculosis; guidelines","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.lpm.2017.01.016_bib0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw566","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/cid\/ciw677","article-title":"Therapeutic drug monitoring in tuberculosis: practical application for physicians","volume":"64","author":"Alffenaar","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/cid\/ciw679","article-title":"Reply to Alffenaar et al","volume":"64","author":"Peloquin","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.016_bib0065","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.016_bib0070","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.016_bib0075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.016_bib0080","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1183\/13993003.00432-2015","article-title":"Classification of antituberculosis drugs: a new proposal based on the most recent evidence","volume":"46","author":"Caminero","year":"2015","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.016_bib0085","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.21037\/jtd.2016.10.14","article-title":"Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives","volume":"8","author":"Rendon","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0090","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardised, treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0095","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Succesful \u20189- month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 55\u00a0consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuber Lung Dis"},{"issue":"10037","key":"10.1016\/j.lpm.2017.01.016_bib0105","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(16)30729-2","article-title":"WHO recommendations on shorter treatment of multidrug-resistant tuberculosis","volume":"387","author":"Sotgiu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.016_bib0110","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01249-2016","article-title":"Faster for less: the new \u2018shorter\u2019 regimen for multidrug-resistant tuberculosis","author":"Sotgiu","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0115","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2014advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.016_bib0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1183\/13993003.00411-2016","article-title":"Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?","volume":"48","author":"Guglielmetti","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.016_bib0130","doi-asserted-by":"crossref","first-page":"e67030","DOI":"10.1371\/journal.pone.0067030","article-title":"Randomized clinical trial of thrice- weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients","volume":"8","author":"Jawahar","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.016_bib0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1183\/09031936.00036812","article-title":"Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones","volume":"40","author":"Migliori","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0140","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0732-8893(91)90002-W","article-title":"Oxazolidinone, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721\u00a0against Mycobacterium tuberculosis","volume":"14","author":"Ashtekar","year":"1991","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0145","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1183\/09031936.00145014","article-title":"Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0160","first-page":"560","article-title":"Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh","volume":"8","author":"Van Deun","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0165","first-page":"758","article-title":"Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands","volume":"4","author":"Geerligs","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.016_bib0175","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500\u00a0consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0180","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1128\/AAC.49.7.2816-2821.2005","article-title":"Imipenem for treatment of tuberculosis in mice and humans","volume":"49","author":"Chambers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lpm.2017.01.016_bib0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.lpm.2017.01.016_bib0190","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0195","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/13993003.00705-2016","article-title":"Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.016_bib0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1183\/13993003.02146-2015","article-title":"Effectiveness and safety of meropenem\/clavulanate-containing regimens in the treatment of MDR- and XDR-TB","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.016_bib0205","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/cid\/ciw088","article-title":"Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"62","author":"Tiberi","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0210","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.016_bib0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"\u03b2-Lactams against Tuberculosis\u00a0\u2013\u00a0new trick for an old dog?","volume":"375","author":"Diacon","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/13993003.01278-2015","article-title":"Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0225","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(98)07399-1","article-title":"Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, C\u00f4te d\u2019Ivoire: a randomised trial","volume":"353","author":"Anglaret","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.016_bib0230","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(10)60057-8","article-title":"Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort","volume":"375","author":"Walker","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.016_bib0235","doi-asserted-by":"crossref","first-page":"e83750","DOI":"10.1371\/journal.pone.0083750","article-title":"Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV","volume":"9","author":"Hoffmann","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0240","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1183\/09031936.00113713","article-title":"Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis","volume":"43","author":"Alsaad","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.016_bib0245","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.00321-2015","article-title":"Mefloquine as a potential drug against multidrug-resistant tuberculosis","volume":"46","author":"Krieger","year":"2015","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.016_bib0250","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero JA1","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.lpm.2017.01.016_bib0255","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","article-title":"New drugs for the treatment of tuberculosis: hope and reality","volume":"16","author":"Grosset","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5707","key":"10.1016\/j.lpm.2017.01.016_bib0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.016_bib0265","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1183\/09031936.00122313","article-title":"Bedaquiline in MDR\/XDR-TB cases: first experience on compassionate use","volume":"43","author":"Tiberi","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.016_bib0275","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09031936.00128613","article-title":"Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient","volume":"43","author":"van Halsema","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0280","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The Diarylquinoline TMC207\u00a0for Multidrug-Resistant Tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0285","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0290","first-page":"1","article-title":"Provisional CDC Guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lpm.2017.01.016_bib0295","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00411-2016","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","author":"Guglielmetti","year":"2016","journal-title":"ERJ"},{"key":"10.1016\/j.lpm.2017.01.016_bib0300","article-title":"Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons not to repeat past errors","author":"Veziris","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0305","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1473-3099(16)00047-5","article-title":"Bedaquiline plus delamanid for XDR tuberculosis","volume":"16","author":"Lach\u00e2tre","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0310","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.016_bib0315","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1183\/13993003.01207-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Wallis","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.016_bib0320","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1183\/13993003.01552-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.016_bib0325","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1183\/13993003.01980-2015","article-title":"First experience of effectiveness and safety of bedaquiline for 18\u00a0months within an optimised regimen for XDR-TB","volume":"47","author":"Lewis","year":"2016","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.lpm.2017.01.016_bib0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030466","article-title":"Derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLOS Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0335","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for Multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.016_bib0340","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.016_bib0345","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1183\/09031936.00060414","article-title":"ERS\/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use","volume":"44","author":"Esposito","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0350","series-title":"The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents: Interim Policy Guidance","author":"World Health Organization","year":"2016"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.016_bib0355","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II dose-ranging trial of the early bactericidal activity of PA-824","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"9979","key":"10.1016\/j.lpm.2017.01.016_bib0360","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.016_bib0365","series-title":"WHO Factsheet: the Shorter MDR-TB regimen","author":"WHO","year":"2016"},{"key":"10.1016\/j.lpm.2017.01.016_bib0370","series-title":"Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials","first-page":"29","author":"Moodley","year":"2016"},{"key":"10.1016\/j.lpm.2017.01.016_bib0375","unstructured":"Clinical Trials Gov NCT02333799. https:\/\/clinicaltrials.gov [accessed 23rd October 2016]."},{"key":"10.1016\/j.lpm.2017.01.016_bib0380","series-title":"OA-3117\u00a0presented at the 47th Union World Conference on Lung Health","article-title":"Interim results of nix-TB clinical study of pretomanid, bedaquiline and linezolid for treatment of XDR and treatment intolerant\/failed MDR-TB","author":"Conradie","year":"2016"},{"key":"10.1016\/j.lpm.2017.01.016_bib0385","series-title":"Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK","first-page":"1","author":"Wolfson","year":"2015"},{"key":"10.1016\/j.lpm.2017.01.016_bib0390","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","article-title":"New agents for the treatment of drug-resistant Mycobacterium tuberculosis","volume":"102","author":"Hoagland","year":"2016","journal-title":"Adv Drug Deliv Rev A"},{"issue":"20","key":"10.1016\/j.lpm.2017.01.016_bib0395","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMc1505196","article-title":"Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis","volume":"370","author":"Bloemberg","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0400","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/bmj.1.4769.1162","article-title":"Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials","volume":"1","author":"Daniels","year":"1952","journal-title":"Br Med J"},{"key":"10.1016\/j.lpm.2017.01.016_bib0405","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1258\/jrsm.99.10.531","article-title":"The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line","volume":"99","author":"Crofton","year":"2006","journal-title":"J R Soc Med"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.016_bib0410","doi-asserted-by":"crossref","first-page":"e70064","DOI":"10.1371\/journal.pone.0070064","article-title":"Patterns of treatment interruption among patients with multidrug-resistant TB (MDR-TB) and association with interim and final treatment outcomes","volume":"8","author":"Podewils","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2017.01.016_bib0415","series-title":"Procurement of second-line anti-tuberculosis drugs for dots-plus pilot projects WHO Working Group on DOTS-Plus for MDR-TB","author":"Gupta","year":"1999"},{"key":"10.1016\/j.lpm.2017.01.016_bib0420","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0425","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0430","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/1745-6215-15-353","article-title":"Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial","volume":"15","author":"Nunn","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.lpm.2017.01.016_bib0435","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1056\/NEJMc066207","article-title":"Gatifloxacin and dysglycemia in older adults","volume":"354","author":"Ittner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0440","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.5588\/ijtld.15.0884","article-title":"Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis","volume":"20","author":"Chiang","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.lpm.2017.01.016_bib0445","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1753-6561-9-S8-S1","article-title":"Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting","volume":"9","author":"Mitnick","year":"2015","journal-title":"BMC Proc"},{"key":"10.1016\/j.lpm.2017.01.016_bib0450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-016-0610-x","article-title":"What can we offer to 3\u00a0million MDRTB household contacts in 2016?","volume":"14","author":"Moore","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.lpm.2017.01.016_bib0455","doi-asserted-by":"crossref","first-page":"e0149372","DOI":"10.1371\/journal.pone.0149372","article-title":"Epidemiology, diagnosis and management of extra-pulmonary tuberculosis in a low-prevalence country: a four year retrospective study in an Australian tertiary infectious diseases unit","volume":"11","author":"Pollett","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2017.01.016_bib0460","series-title":"Tuberculosis in England 2015\u00a0Report","author":"PHE","year":"2015"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:04:16Z","timestamp":1750021456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498217300568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0755498217300568"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.016","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of the new tuberculosis drugs","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}